Results 271 to 280 of about 77,108 (288)

Ipilimumab

Reactions Weekly, 2019
  +6 more sources

Ipilimumab

Reactions Weekly, 2012
openaire   +2 more sources

Ipilimumab

Reactions Weekly, 2014
openaire   +2 more sources

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2022
Jedd D Wolchok, Vanna Chiarion Sileni, Jean-Jacques Grob   +2 more
exaly  

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nature Medicine, 2020
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina   +2 more
exaly  

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Lancet Oncology, The, 2021
Luis Paz-Ares, , Enriqueta Felip
exaly  

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Nature Medicine, 2023
J. van Dorp, C. Pipinikas, B. Suelmann, N. Mehra, N. van Dijk, G. Marsico, M. V. van Montfoort, S. Hackinger, Linde M. Braaf, T. Amarante, Charlaine van Steenis, K. McLay, A. Daletzakis, D. van den Broek, M. van de Kamp, K. Hendricksen, J. D. de Feijter, T. Boellaard, R. Meijer, A. G. van der Heijden, N. Rosenfeld, B. V. van Rhijn, Greg Jones, M. S. van der Heijden   +23 more
semanticscholar   +1 more source

Ipilimumab

Reactions Weekly, 2023
openaire   +2 more sources

Immunotherapy of cancer in 2012

Ca-A Cancer Journal for Clinicians, 2012
Lisa H Butterfield, Ahmad A Tarhini
exaly